Treatment With Pazopanib for Neoadjuvant Breast Cancer

This is a phase II non-randomized, multi-center study aimed to evaluate the efficacy and
safety of the combination of pazopanib and paclitaxel following treatment with
cyclophosphamide and doxorubicin for the treatment of neoadjuvant breast cancer.

Patients will receive standard doses of AC every 21 days for 4 cycles. This will be followed
by weekly paclitaxel 80 mg/m2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given
concurrently with pazopanib 800 mg PO daily starting with the first paclitaxel dose and
continuing until 7 days before surgery. Clinical complete response rate will be determined
by tumor assessments performed by palpation at two time points: following AC (before
paclitaxel/pazopanib begins) and 2-4 weeks following the last dose of paclitaxel (before
surgery). Following recovery from preoperative therapy, patients will undergo the
clinically-indicated surgery. Pazopanib will resume 4-6 weeks after surgery and continue
daily for 6 months of postoperative pazopanib therapy.